SCHEMBL25923944

SCHEMBL25923944

CCCCCC(CCCC)CCCN1CC2(CCN(C(=O)C(CCC)CCC)CC2)C1

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.35
LMNA P02545 1/20 0.35
USP2 O75604 2/20 0.34
S1PR1 P21453 2/20 0.33
S1PR3 Q99500 2/20 0.33
S1PR5 Q9H228 2/20 0.33
S1PR4 O95977 1/20 0.33
EPHX2 P34913 1/20 0.32
ALDH1A1 P00352 1/20 0.32
CYP2D6 P10635 2/20 0.32
CHRM3 P20309 1/20 0.31
CCKBR P32239 1/20 0.31
CA2 P00918 1/20 0.31
CYP2C19 P33261 2/20 0.30
CYP1A2 P05177 2/20 0.30
HIF1A Q16665 2/20 0.30
DRD2 P14416 1/20 0.30
DRD3 P35462 1/20 0.30
CYP2C9 P11712 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25707635 0.95 LMNA (0.37) TSHRLMNAUSP2S1PR1S1PR3
SCHEMBL23945776 0.93 LMNA (0.37) TSHRLMNAUSP2S1PR1S1PR3
SCHEMBL24673675 0.93 LMNA (0.38) TSHRLMNAUSP2S1PR1S1PR3
SCHEMBL25884460 0.91 LMNA (0.37) TSHRLMNAUSP2S1PR1S1PR3
SCHEMBL26405356 0.91 USP2 (0.38) TSHRLMNAUSP2S1PR1S1PR3
SCHEMBL25122691 0.90 TSHR (0.37) TSHRLMNAUSP2S1PR1S1PR3
SCHEMBL25927357 0.90 TSHR (0.37) TSHRLMNAUSP2S1PR1S1PR3
SCHEMBL25123610 0.87 ACE2 (0.38) TSHRLMNAUSP2S1PR1S1PR3
SCHEMBL25707293 0.87 TSHR (0.39) TSHRLMNAUSP2EPHX2ALDH1A1
SCHEMBL25480360 0.86 USP2 (0.41) TSHRLMNAUSP2S1PR1S1PR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234953-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234953-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 TSHR 3319/4885LMNA 1656/4885USP2 141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.